Contribution of fluorodeoxyglucose positron-emission tomography combined with magnetic resonance imaging for differential diagnosis between radionecrosis and recurrence of treated brain metastasis.

Fiche publication

Date publication

juillet 2026

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NAMER Izzie-Jacques , Pr NOEL Georges , Dr BUND Caroline

Tous les auteurs :
Bessac D, Kaseb A, Baloglu S, Todeschi J, Noël G, Namer IJ, Bund C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42413447

Résumé

Differentiating between changes after radiotherapy and radionecrosis during the follow-up of brain metastasis remains challenging. Hybrid positron-emission tomography/magnetic resonance imaging is a relatively novel imaging modality that integrates advanced magnetic resonance imaging sequences with metabolic data from positron-emission tomography. This study ailed to evaluate retrospectively the contribution of hybrid (F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging in distinguishing radionecrosis from recurrent cerebral metastatis, comparing the diagnosis performance of (F)-fluorodeoxyglucose positron-emission tomography and magnetic resonance imaging independently, without relying clinical or prior imaging data.